EpiLift System Receives Approval from the Japanese Health Minister.

IRVINE, Calif. -- VisiJet, Inc. (OTC BB: VJET) dba Advanced Refractive Technologies (ART), a developer and marketer of innovative technologies for the ophthalmic surgical market, has received approval from the Health Ministry of Japan to market and sell its EpiLift System, a medical device that enables a potentially safer form of laser eye surgery called Epi-LASIK.

The EpiLift System, approved by the U.S. Food and Drug Administration in late 2004, is the cornerstone of Epi-LASIK, a new method of the popular LASIK corrective vision procedure. Unlike LASIK, Epi-LASIK allows the eye to heal completely post-operation, minimizing the risk of complications such as dry eye or vision impairment.

"The Japanese market is particularly concerned about safety with these kinds of procedures, which, to some extent, delayed and limited LASIK's penetration into the Japanese marketplace," said Randy Bailey, chief executive officer. "The Health Ministry's approval of our EpiLift system is a huge validation. We are excited to be able to offer this exciting technology to the Japanese ophthalmic community."

About the EpiLift System

When the EpiLift System is used, the epithelium - the top layer of the eye - is cleanly separated, at a natural division point in the eye, from the Bowman's layer membrane in an intact sheet of viable tissue. The tissue is then lifted away from the cornea so that a laser can be applied to reshape it. This entire process, Epi-LASIK, produces virtually instant visual results similar to LASIK but with the stable long-term visual outcomes of PRK.

LASIK surgery, currently a standard corrective vision surgical process, requires making a flap in the top layer of the eye before the laser is applied. This flap, once created, never fully heals, which can lead to complications and possible vision impairment in the future. Because it does not involve cutting the cornea or creating a permanent flap, the EpiLift System allows the eye to regrow the connections with the epithelium, resulting in a safer procedure with a significantly lower risk of complications.

About VisiJet

VisiJet, Inc. is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. The EpiLift system is manufactured in Germany by Gebauer Medizintechnik GmbH.

In addition to the EpiLift system, VisiJet is developing HydroKeratome(R) and Pulsatome(R), which utilize the company's proprietary and patented waterjet technology. These products result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. HydroKeratome(R) uses the waterjet technology, employing a high-pressure micro beam of water with the diameter of a human hair to cut the corneal flap as required in LASIK surgery. The Pulsatome(R) cataract emulsifier, currently under development, is a device that uses pulsed waterjet technology to remove cataracts - the most frequently performed surgical procedure in the world.